Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02811861
Registration number
NCT02811861
Ethics application status
Date submitted
21/06/2016
Date registered
23/06/2016
Date last updated
10/07/2023
Titles & IDs
Public title
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Query!
Scientific title
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)
Query!
Secondary ID [1]
0
0
KEYNOTE-581
Query!
Secondary ID [2]
0
0
E7080-G000-307
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CLEAR
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Renal Cell Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lenvatinib
Treatment: Drugs - Everolimus
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Sunitinib
Experimental: Lenvatinib 18 mg plus Everolimus 5 mg - Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily in each 21-day cycle.
Experimental: Lenvatinib 20 mg plus Pembrolizumab 200 mg - Lenvatinib 20 mg administered orally, once daily, in each 21-day cycle plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks on Day 1 of each 21-day cycle.
Active Comparator: Sunitinib 50 mg - Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment in each 21-day cycle.
Treatment: Drugs: Lenvatinib
Treatment: Drugs: Everolimus
Treatment: Drugs: Pembrolizumab
Treatment: Drugs: Sunitinib
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS) by Independent Imaging Review (IIR)
Query!
Assessment method [1]
0
0
PFS assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or death (whichever occurred first) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method.
Query!
Timepoint [1]
0
0
From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)
Query!
Secondary outcome [1]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
ORR is defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by IIR using RECIST 1.1. CR is defined as disappearance of all (targeted and non-target [NT]) lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (<) 10mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [1]
0
0
Up to approximately 69 months
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS is defined as the time from the date of randomization to the date of death from any cause. Participants who were lost to follow-up and those who were alive at the data cutoff date were censored, either at the last date the participant was last known alive or at the data cutoff date, whichever occurred first. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [2]
0
0
Up to approximately 69 months
Query!
Secondary outcome [3]
0
0
Number of Participants With At Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [3]
0
0
TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug.An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A SAE was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [3]
0
0
Up to approximately 69 months
Query!
Secondary outcome [4]
0
0
Number of Participants Who Discontinued Treatment Due to Toxicity
Query!
Assessment method [4]
0
0
Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [4]
0
0
Up to approximately 69 months
Query!
Secondary outcome [5]
0
0
Time to Treatment Failure Due to Toxicity
Query!
Assessment method [5]
0
0
Time to treatment failure due to toxicity is defined as time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [5]
0
0
Up to approximately 69 months
Query!
Secondary outcome [6]
0
0
Health-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores
Query!
Assessment method [6]
0
0
The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [6]
0
0
Up to approximately 69 months
Query!
Secondary outcome [7]
0
0
HRQoL Assessed by European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Score
Query!
Assessment method [7]
0
0
EORTC QLQ-C30 is a questionnaire including 30 questions that rate the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. For the overall HRQoL and functioning scales, a higher score is correlated with better HRQoL, whereas a higher score represents worse HRQoL for symptom scales. Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [7]
0
0
Up to approximately 69 months
Query!
Secondary outcome [8]
0
0
HRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Score
Query!
Assessment method [8]
0
0
EQ-5D-3L is a health profile questionnaire consisting of the EQ-5D descriptive system and the EuroQol visual analog scale (EQ-VAS). For the EQ-5D, participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) at 1 of 3 levels (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 (full health) to <0 (worse health/dead). The EQ-VAS measures self-rated global health status using a vertically oriented VAS, where 100 represents the "best imaginable health state" and 0 represents the "worst imaginable health state." Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [8]
0
0
Up to approximately 69 months
Query!
Secondary outcome [9]
0
0
PFS on Next-line of Therapy (PFS2)
Query!
Assessment method [9]
0
0
PFS2 is defined as the time from randomization to disease progression as assessed by investigator on next-line treatment or death from any cause (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [9]
0
0
Up to approximately 69 months
Query!
Secondary outcome [10]
0
0
PFS by Investigator Assessment
Query!
Assessment method [10]
0
0
PFS by investigator assessment is defined as the time from the date of randomization to the date of first documentation of disease progression based on the investigator assessment per RECIST 1.1 or death (whichever occurred first). Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [10]
0
0
Up to approximately 69 months
Query!
Secondary outcome [11]
0
0
Model-predicted Clearance for Lenvatinib and Everolimus
Query!
Assessment method [11]
0
0
Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [11]
0
0
Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length=21 days)
Query!
Secondary outcome [12]
0
0
Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib and Everolimus
Query!
Assessment method [12]
0
0
Data for this outcome measure will be reported after study completion (anticipated study completion date is July 2022).
Query!
Timepoint [12]
0
0
Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length = 21 days
Query!
Eligibility
Key inclusion criteria
1. Histological or cytological confirmation of RCC with a clear-cell component (original
tissue diagnosis of RCC is acceptable).
2. Documented evidence of advanced RCC.
3. At least 1 measurable target lesion according to RECIST 1.1 meeting the following
criteria:
- Lymph node (LN) lesion that measures at least 1 dimension as greater than or
equal to (>=) 1.5 cm in the short axis
- Lymph node (LN) lesion that measures at least 1 dimension as greater than or
equal to (>=) 1.5 centimeter (cm) in the short axis
- Non-nodal lesion that measures greater than or equal to (>=) 1.0 cm in the
longest diameter
- The lesion is suitable for repeat measurement using computerized
tomography/magnetic resonance imaging (CT/MRI). Lesions that have had external
beam radiotherapy (EBRT) or locoregional therapy must show radiographic evidence
of disease progression based on RECIST 1.1 to be deemed a target lesion.
3.Karnofsky Performance Status (KPS) of >=70 4.Adequately controlled blood pressure (BP)
with or without antihypertensive medications, defined as BP less than or equal (<=) 150/90
millimeter of mercury (mmHg) at Screening and no change in antihypertensive medications
within 1 week prior to Cycle 1/Day 1 (C1/D1) 5.Adequate renal function defined as
creatinine <=1.5*upper limit of normal (ULN); or for participants with creatinine greater
than (>) 1.5*ULN, the calculated creatinine clearance >=30 milliliters per minute (mL/min)
(per the Cockcroft-Gault formula) is acceptable.
6.Adequate bone marrow function defined by:
- Absolute neutrophil count (ANC) >=1500/cubic millimeter (mm^3)
- Platelets >=100,000/mm^3
- Hemoglobin >=9 grams per deciliter (g/dL) NOTE: Criteria must be met without
erythropoietin dependency and without packed red blood cell (pRBC) transfusion within
the previous 2 weeks.
7.Adequate blood coagulation function defined by International Normalized ratio (INR)
<=1.5 unless participant is receiving anticoagulant therapy, as long as INR is within
therapeutic range of intended use of anticoagulants.
8.Adequate liver function defined by:
- Total bilirubin <=1.5*ULN except for unconjugated hyperbilirubinemia of Gilbert's
syndrome.
- Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate
aminotransferase (AST) <=3*ULN (in the case of liver metastases <=5*ULN), unless there
are bone metastases. Participants with ALP values >3*ULN and known to have bone
metastases can be included.
9.Provide written informed consent. 10.Willing and able to comply with all aspects of
the protocol.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participants who have received any systemic anticancer therapy for RCC, including
anti-vascular endothelial growth factor (VEGF) therapy, or any systemic
investigational anticancer agent. Prior adjuvant treatment with an investigational
anticancer agent is not allowed unless the investigator can provide evidence of
participant's randomization to placebo arm.
2. Participants with central nervous system (CNS) metastases are not eligible, unless
they have completed local therapy (example, whole brain radiation therapy (WBRT),
surgery or radiosurgery) and have discontinued the use of corticosteroids for this
indication for at least 4 weeks before starting treatment in this study. Any signs
(example, radiologic) or symptoms of CNS metastases must be stable for at least 4
weeks before starting study treatment
3. Active malignancy (except for RCC, definitively treated basal or squamous cell
carcinoma of the skin, and carcinoma in-situ of the cervix or bladder) within the past
24 months. Participants with history of localized & low risk prostate cancer are
allowed in the study if they were treated with curative intent and there is no
prostate specific antigen (PSA) recurrence within the past 5 years
4. Prior radiation therapy within 21 days prior to start of study treatment with the
exception of palliative radiotherapy to bone lesions, which is allowed if completed 2
weeks prior to study treatment start
5. Participants who are using other investigational agents or who had received
investigational drugs <=4 weeks prior to study treatment start.
6. Received a live vaccine within 30 days of planned start of study treatment (Cycle
1/Day 1). Examples of live vaccines include, but are not limited to, measles, mumps,
rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
are generally killed virus vaccines and are allowed; however, intranasal influenza
vaccines (example, FluMist®) are live attenuated vaccines and are not allowed.
7. Participants with proteinuria >1+ on urine dipstick testing will undergo 24-h urine
collection for quantitative assessment of proteinuria. Participants with urine protein
>=1 g/24 h will be ineligible
8. Fasting total cholesterol >300 milligram per deciliter (mg/dL) (or ?7.75 millimole per
liter (mmol/L)) and/or fasting triglycerides level ?2.5 x upper limit of normal (ULN).
Note: these participants can be included after initiation or adjustment of
lipid-lowering medication
9. Uncontrolled diabetes as defined by fasting glucose >1.5 times the ULN. Note: these
participants can be included after initiation or adjustment of glucose-lowering
medication
10. Prolongation of corrected QT (QTc) interval to >480 milliseconds (ms)
11. Participants who have not recovered adequately from any toxicity and/or complications
from major surgery prior to starting therapy.
12. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition
that might affect the absorption of lenvatinib, everolimus, and/or sunitinib.
13. Bleeding or thrombotic disorders or participants at risk for severe hemorrhage. The
degree of tumor invasion/infiltration of major blood vessels should be considered
because of the potential risk of severe hemorrhage associated with tumor
shrinkage/necrosis following lenvatinib therapy
14. Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first
dose of study drug
15. Significant cardiovascular impairment within 12 months of the first dose of study
drug: history of congestive heart failure greater than New York Heart Association
Class II, unstable angina, myocardial infarction, cerebrovascular accident, or cardiac
arrhythmia associated with hemodynamic instability. The following is also excluded:
left ventricular ejection fraction (LVEF) below the institutional normal range as
determined by multiple-gated acquisition MUGA scan or echocardiogram
16. Active infection (any infection requiring systemic treatment)
17. Participants known to be positive for Human Immunodeficiency Virus (HIV).
18. Known active Hepatitis B (example, Hepatitis B surface antigen (HBsAg) reactive) or
Hepatitis C (example, hepatitis C virus ribonucleic acid (HCV RNA) [qualitative] is
detected)
19. Known history of, or any evidence of, interstitial lung disease
20. Has a history of (non-infectious) pneumonitis that required steroids, or current
pneumonitis
21. Participants with a diagnosis of immunodeficiency or who are receiving chronic
systemic steroid therapy (doses exceeding 10 mg/day of prednisone equivalent) or any
other form of immunosuppressive therapy within 7 days prior to the first dose of study
treatment. Physiologic doses of corticosteroids (up to 10 mg/day of prednisone or
equivalent) may be used during the study
22. Active autoimmune disease (with the exception of psoriasis) that has required systemic
treatment in the past 2 years (that is, with use of disease modifying agents,
corticosteroids or immunosuppressive drugs). Replacement therapy (example, thyroxine,
insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency) is not considered a form of systemic treatment.
23. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a
positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin
[hCG]) test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG [or
hCG]). A separate baseline assessment is required if a negative screening pregnancy
test was obtained more than 72 hours before the first dose of study drug.
24. Females of childbearing potential who:
- Do not agree to use a highly effective method of contraception for the entire
study period and for 120 days after study discontinuation, that is:
- total abstinence (if it is their preferred and usual lifestyle)
- an intrauterine device (IUD) or hormone-releasing system (IUS)
- a contraceptive implant
- an oral contraceptive (with additional barrier method) OR
- Do not have a vasectomized partner with confirmed azoospermia. For sites outside
of the EU, it is permissible that if a highly effective method of contraception
is not appropriate or acceptable to the participant, then the participant must
agree to use a medically acceptable method of contraception, that is, double
barrier methods of contraception such as condom plus diaphragm or cervical/vault
cap with spermicide.
25. Males who have not had a successful vasectomy (confirmed azoospermia) and do not agree
to use condom + spermicide OR have a female partner who does not meet the criteria
above (that is, is of childbearing potential and not practicing highly effective
contraception throughout the study period), starting with the first dose of study
therapy through 120 days after the last dose of study therapy, unless sexually
abstinent. Note: Abstinence is acceptable if this is the usual lifestyle and preferred
contraception for the participant.
26. Known intolerance to any of the study drugs (or any of the excipients)
27. Participant has had an allogenic tissue/solid organ transplant.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/10/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/07/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1069
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Eastern Clinical Research Unit - Box Hill
Query!
Recruitment hospital [2]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [3]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [4]
0
0
Macquarie University Hospital - Macquarie park
Query!
Recruitment hospital [5]
0
0
ICON Cancer Foundation - South Brisbane
Query!
Recruitment hospital [6]
0
0
Sunshine Hospital - St Albans
Query!
Recruitment postcode(s) [1]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [2]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [3]
0
0
- Hobart
Query!
Recruitment postcode(s) [4]
0
0
- Macquarie park
Query!
Recruitment postcode(s) [5]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [6]
0
0
- St Albans
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Louisiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nebraska
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
South Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Innsbruck
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Linz
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Vienna
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Aalst
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Antwerpen
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Bonheiden
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Bruxelles
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Hasselt
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Liege
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Wilrijk
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Alberta
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
British Columbia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Quebec
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Brno
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Olomouc
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Praha 4
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Praha 5
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Praha 8
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Maine Et Loire
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Dijon cedex
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Le Mans Cedex
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Lyon
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Montpellier
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Paris
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Saint Herblain
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Strasbourg
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Baden Wuerttemberg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Bayern
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Hessen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Mecklenburg-Vorpommern
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Niedersachsen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Nordrhein Westfalen
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Saarland
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Berlin
Query!
Country [52]
0
0
Greece
Query!
State/province [52]
0
0
Athens
Query!
Country [53]
0
0
Greece
Query!
State/province [53]
0
0
Patras
Query!
Country [54]
0
0
Greece
Query!
State/province [54]
0
0
Thessaloníki
Query!
Country [55]
0
0
Ireland
Query!
State/province [55]
0
0
Cork
Query!
Country [56]
0
0
Ireland
Query!
State/province [56]
0
0
Dublin
Query!
Country [57]
0
0
Ireland
Query!
State/province [57]
0
0
Galway
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Be'er Ya'aqov
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Haifa
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Kfar-Saba
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Petah Tikva
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Ramat-Gan
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Tel Aviv
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Ravenna
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Arezzo
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Bologna
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Genova
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Lecce
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Meldola
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Milano
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Modena
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Napoli
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Pavia
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Pordenone
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Roma
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Rome
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Aichi
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Akita
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Aomori
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Chiba
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Fukuoka
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Hiroshima
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Hokkaido
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Hyogo
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Kagawa
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Kanagawa
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Nagasaki
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Nara
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Niigata
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Okayama
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Osaka
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Saitama
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Tokushima
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Tokyo
Query!
Country [95]
0
0
Korea, Republic of
Query!
State/province [95]
0
0
Daegu
Query!
Country [96]
0
0
Korea, Republic of
Query!
State/province [96]
0
0
Goyang-si
Query!
Country [97]
0
0
Korea, Republic of
Query!
State/province [97]
0
0
Seoul
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Amsterdam
Query!
Country [99]
0
0
Netherlands
Query!
State/province [99]
0
0
Utrecht
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Gdansk
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Lublin
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Szczecin
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Moscow
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
Nizhniy Novgorod
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
Novosibirsk
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Obninsk
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
Omsk
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Cantabria
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Barcelona
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Caceres
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Cordoba
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Madrid
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Oviedo
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Seville
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Valencia
Query!
Country [116]
0
0
Switzerland
Query!
State/province [116]
0
0
Bern
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Bournemouth
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Cardiff
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Edinburgh
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Glasgow
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Leeds
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
London
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eisai Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Merck Sharp & Dohme LLC
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary purpose of the study is to demonstrate that lenvatinib in combination with
everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C)
in improving progression-free survival (PFS) (by independent imaging review [IIR] using
Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) as first-line treatment in
participants with advanced renal cell carcinoma (RCC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02811861
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02811861
Download to PDF